Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting

On October 31, 2023 Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported new preclinical data for AB821, its CD8-targeted interleukin-21 (IL-21) immunotherapy (Press release, Asher Biotherapeutics, OCT 31, 2023, View Source [SID1234636595]). The data will be presented at the Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, being held in San Diego, CA on November 1-5, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to share new preclinical data for AB821 at SITC (Free SITC Whitepaper), further illustrating the potential of our highly differentiated cis-targeted immunotherapies for the treatment of cancer," said Andy Yeung, Ph.D., Chief Technology Officer and Co-founder of Asher Bio. "IL-21 has historically demonstrated promising antitumor activity, but its clinical use has been limited due to toxicities and pleiotropic effects. We designed AB821 to activate only CD8+ T cells, the immune cell type driving the antitumor response, potentially maximizing the efficacy of IL-21 and limiting off-target activity. The new preclinical data presented at SITC (Free SITC Whitepaper) demonstrate that AB821 can improve the functionality of exhausted CD8+ T cells and promote their function and survival to effectively facilitate potent antitumor activity. Based on these data, we believe AB821 could significantly improve the treatment paradigm for patients with tumor types unresponsive to checkpoint blockade therapies, who typically have highly exhausted CD8+ T cells in their tumors. We look forward to advancing AB821’s clinical development and remain on track to file an IND in the fourth quarter of 2023."

New Preclinical Data for AB821, Asher Bio’s CD8-Targeted IL-21

In a poster presentation entitled, "AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that reduces CD8+ T cell exhaustion to induce potent antitumor activity," lead author Renee Greer, Ph.D., Principal Scientist at Asher Bio, described new preclinical data further characterizing the mechanisms by which AB821 enhances the functionality of CD8+ T cells and facilitates the antitumor effects of IL-21, further supporting AB821’s development. The data show:

A murine surrogate of AB821 (muAB821) demonstrated potent antitumor activity both as a monotherapy and in combination with anti-PD-1 therapy in anti-PD-1 refractory mouse tumor models.
Exhausted CD8+ T cells are a promising target for AB821 therapy, as supported by the following:
High levels of IL-21R were observed in the exhausted CD8+ T cell subset in mouse tumors and in human tumor-infiltrating lymphocytes (TILs)
Treatment with muAB821 resulted in replacement of exhausted CD8+ T cells with CD8+ T cells with restored cytotoxic potential and expressing memory markers.
In human TILs, exhausted CD8+ T cells were shown to be highly responsive to treatment with AB821 as measured by pSTAT3 sensitivity.
In human TILs cultured with AB821, AB821 acted on exhausted CD8+ T cells to improve their antitumor functionality by increasing expression and secretion of key effector proteins such as Granzyme B and perforin, both of which are essential for antitumor activity.
Clinical Trial in Progress for AB248, Asher Bio’s CD8-Targeted IL-2

Also at SITC (Free SITC Whitepaper), a poster highlighting Asher Bio’s lead immunotherapy candidate, AB248, a CD8+ T cell-selective IL-2, will be featured in a clinical trial in progress poster. The poster, entitled "An open-label, Phase 1a/b study of AB248, a CD8+ T selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors," details the design of the ongoing Phase 1a/1b study of AB248 alone and in combination with pembrolizumab in patients with advanced solid tumors who failed prior standard of care treatments (NCT05653882). Asher Bio initiated this Phase 1a/1b study in January 2023.

Both poster presentations will be available in the "Presentations and Posters" section of Asher Bio’s website: View Source

About AB821

IL-21 is a cytokine that activates STAT3, a master transcription factor involved in a broad spectrum of adaptive and innate immune functions. In oncology, IL-21 has historically demonstrated promising in early clinical studies, but was hindered by toxicities and pleiotropic effects, such as suppression of antigen presentation, which could dampen overall antitumor efficacy. Asher Bio hypothesized that focusing the activity of IL-21 to only the immune cell type primarily responsible for antitumor efficacy, while avoiding activation of other cells, would maximize the efficacy potential of IL-21 and reduce toxicity. Like IL-2, IL-21 derives its benefit from stimulating CD8+ T cells, but it mediates antitumor activity via a distinct, potentially complementary pathway. Asher Bio developed AB821 as a cis-targeted IL-21 activating cytokine that selectively targets CD8+ T cells, the immune cell type driving antitumor response. The IL-21 activating cytokine promotes cytotoxicity, memory cell differentiation, survival and reinvigoration of CD8+ T cells, all of which support antitumor activity. Asher Bio believes that AB821 has the potential to treat tumor types that may not be responsive to IL-2 and/or PD-1 therapy. PD-1-resistant tumors are associated with reduced memory T cell numbers and increased exhausted T cell numbers, suggesting that this molecule may be beneficial in these resistant tumors. AB821 also has the potential to be used in combination with AB248 to enhance efficacy by combining a proliferation signal with one that optimizes functionality and prevents T cell exhaustion.

Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting

On October 31, 2023 Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, reported initial data from the company’s ongoing Phase 1/2 study of NDI-101150, a small-molecule inhibitor of HPK1, which are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting in San Diego, CA (Press release, Nimbus Therapeutics, OCT 31, 2023, View Source [SID1234636594]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data presented at SITC (Free SITC Whitepaper) include initial safety and efficacy results from single agent therapy (n=13) in the dose escalation portion of the trial. Monotherapy treatment with NDI-101150 resulted in clinical benefit in 3 patients: One patient with renal cell carcinoma exhibited a complete response (CR) — the absence of all detectable cancer following treatment — while two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> 6 months) stable disease. Notably, the renal cell carcinoma patient who experienced a CR and clinical benefit with monotherapy NDI-101150 had been previously treated with and progressed on a regimen of nivolumab, an immune checkpoint inhibitor antibody. Furthermore, NDI-101150 demonstrated an acceptable safety profile below 200 mg/day, the identified non-tolerated dose.

"We’re pleased to share these first clinical data from our clinical trial of NDI-101150. We are encouraged by the preliminary efficacy we have seen thus far, which supports the potential of NDI-101150 to provide a meaningful therapeutic option for patients with solid tumors," said Nathalie Franchimont, M.D., Ph.D., Chief Medical Officer of Nimbus. "HPK1 inhibition is an exciting approach because of its potential to activate not just T cells, as checkpoint inhibitors do, but also B cells and dendritic cells. We look forward to sharing future updates on NDI-101150, including data from ongoing combination cohorts and dose expansion cohorts."

The Phase 1/2 trial (NCT05128487) is a multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adults with advanced or metastatic solid tumors.

In a second poster at SITC (Free SITC Whitepaper), Nimbus is presenting new preclinical data which support the potential for both broad immunotherapeutic potential and best-in-class selectivity of NDI-101150 among publicly disclosed HPK1 inhibitor programs to date. NDI-101150 was found to be over 300 times more selective for HPK1 than related proteins in the MAP4K family — potentially reducing off-target effects.

"Our driving purpose at Nimbus is to leverage our expertise and technology to design breakthrough medicines for patients," said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. "The data presented at SITC (Free SITC Whitepaper) reinforce the potential first-in-class and best-in-class profile of our HPK1 inhibitor, and we will continue to work to realize its possible benefits to patients with cancer."

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

On October 31, 2023 CatalYm reported the presentation of two preclinical data sets expanding the mechanistic understanding and clinical application of its lead anti-GDF-15 antibody candidate, visugromab, at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023 Annual Meeting in San Diego, USA (Press release, Catalym, OCT 31, 2023, View Source [SID1234636593]). The findings will be presented in two poster sessions on Friday, November 3rd, and Saturday, November 4th, and provide further clarification on GDF-15-mediated inhibition of T cell infiltration and highlight the potential of combining visugromab with bispecific T-cell engagers as a novel approach in cancer therapy. Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are advancing our understanding of the underlying molecular mechanisms that are the foundation for GDF-15’s central role in tumor resistance to immunotherapy and visugromab’s potential to reinstate anti-tumor activity and enhance responses," said Dr. Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm. "The new data for the combination of visugromab with bispecific T-cell engagers provide strong scientific support for a synergistic effect in this novel therapeutic setting. We will further investigate this combination, which could extend durability and improve outcomes for a broad range of cancer patients with high medical need."

Poster Presentation Identifying SHP-1 as Central Mediator of GDF-15-related T Cell Adhesion Inhibition

The first data set further expands understanding of visugromab’s mechanism of action and the underlying pathways involved in the development of GDF-15-mediated therapy resistance in cancer cells. When investigating the involvement of additional cell adhesion pathway components downstream of GDF-15, SHP-1 was identified as a central mediator of GDF-15-related inhibition of T cell adhesion. SHP-1 is an intracellular tyrosine phosphatase known as a negative regulator of antigen-dependent activation and proliferation of T cells. Inhibition of SHP-1 resulted in abrogation of GDF-15’s inhibitory effect. The researchers confirmed that GDF-15 via SHP-1 inhibits the phosphorylation of ZAP-70, another intracellular tyrosine kinase involved in LFA-1 inside-out activation and T cell receptor signaling. These data connect SHP-1 as a downstream effector to the recently published GDF-15-mediated reduction of high-affinity LFA-1 conformation, leading to impaired endothelial adhesion and transmigration of T cells toward the tumor site.

Poster Presentation Details

Title: SHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T cells
Presenter: Dr. Christine Schuberth-Wagner
Abstract number: 1049
Date and time: Friday, Nov 3rd, 5:00-6:30pm PDT

Poster Presentation on Visugromab/T-Cell Engager Combination

The second data set supports the expansion of visugromab’s application to combinations with immune cell-engaging therapies, underlining its potential to be a critical component for treatment success in a broad range of anti-cancer regimens. The preclinical analyses investigated a new combination of visugromab with a bispecific T-cell engager (tebentafusp). Anti-tumor activity of bispecific T-cell engagers is dependent on infiltration of effector T cells into the tumor microenvironment. In vivo analyses in a mouse tumor model demonstrated that the combination with visugromab significantly increased the number of intratumoral T cells compared with tebentafusp alone. This indicates a direct positive impact of visugromab’s infiltration-enhancing activity on the anti-tumor activity of bispecific T-cell engaging treatments and provides a strong rationale to further investigate this therapeutic concept.

Poster Presentation Details

Title: GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers
Presenter: Dr. Christine Schuberth-Wagner
Abstract number: 1196
Date and time: Saturday, Nov 4th, 7:00-8:30pm PDT

CatalYm is investigating its GDF-15-neutralizing antibody visugromab in a broad Phase 2 clinical program, the GDFather (GDF-15 Antibody-mediaTed Human Effector Cell Relocation) trials, in combination with the anti-PD-1 inhibitor nivolumab in patients with advanced solid tumors. First interim data from the Phase 2 (NCT04725474) trial continue to demonstrate a very good safety and tolerability profile and promising early responses in major cancer indications, including non-small cell lung cancer (NSCLC), bladder cancer and hepatocellular carcinoma (HCC). In addition, CatalYm recently announced an exploratory Phase 2 study, GDFather-NEO (NCT06059547), evaluating visugromab in combination with neoadjuvant immunotherapy in first-line muscle-invasive bladder cancer.

About Visugromab (CTL-002)

Visugromab is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation and tumor infiltration. Visugromab has already demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients The antibody is currently being investigated in ongoing Phase 2 studies in multiple solid tumor indications.

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

On October 31, 2023 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that updated data from the Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, bel-sar, for the first-line treatment of adult patients with early-stage choroidal melanoma will be presented at the upcoming American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023, in San Francisco (Press release, Aura Biosciences, OCT 31, 2023, View Source [SID1234636592]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the paper presentation are as follows:

Title: A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration
Presenter: Carol L. Shields, MD, Wills Eye Hospital
Session #: PA069
Location #: WEST 2006
Date/Time: Monday, November 6, 2023, from 2:54 p.m. to 3:01 p.m. Eastern Time (11:54 a.m. to 12:01 p.m. Pacific Time)

The presentation will be available here on Monday, November 6, 2023, following the presentation.

Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients

On October 31, 2023 Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, reported that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2 study for Radspherin in patients with peritoneal carcinomatosis from ovarian cancer (Press release, Oncoinvent, OCT 31, 2023, View Source [SID1234636591]). This represents the second U.S. FDA IND clearance for Radspherin, as last week, the company also announced an IND acceptance for Radspherin in patients with peritoneal carcinomatosis from colorectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to announce the IND clearance for this phase 2b study of Radspherin, allowing for inclusion of patients in the first-line treatment setting of ovarian cancer," said Anders Månsson, Chief Executive Officer of Oncoinvent. "This IND clearance comes in succession to the IND clearance of Radspherin in colorectal cancer patients, announced recently. With the initiation of two U.S. clinical trials, we look forward to broadening the clinical reach of Radspherin to include both U.S. and Europe. With compelling data supporting Radspherin from both clinical programs, we remain steadfast in our mission and eagerly anticipate moving forward to the next stages of development."

In the phase 1 clinical trial of Radspherin in recurrent ovarian cancer patients, a recommended dose of 7MBq was selected following the completion of dose escalation. Oncoinvent recently presented initial safety data from the ongoing RAD-18-001 study evaluating the dose, safety and tolerability of Radspherin in patients with recurrent ovarian cancer at the 24th Congress of the European Society of Gynaecological Oncology (ESGO). The trial’s safety interim analysis demonstrated that Radspherin was well tolerated with no dose-limiting toxicity observed.

The trial, for which we have now received U.S. FDA clearance, is planned to start in Q2 of 2024. It is a randomized controlled phase 2b trial, assessing efficacy and safety of Radspherin in patients with peritoneal metastasis from ovarian cancer. The primary objective is to compare progression-free survival (PFS) between patients who receive Radspherin after complete surgical resection following pre-operative chemotherapy and patients who only undergo pre-operative chemotherapy and surgery.